Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies is benefiting from a stronger fundamental backdrop as NCCN’s updated multiple myeloma guidelines explicitly name clonoSEQ, favor 10-6 sensitivity, broaden recommended testing frequency, and create a clearer standard-of-care framework that should lift utilization and tests per patient. The core MRD franchise is already showing strong operating momentum, with Q2’26 revenue of $72M, clonoSEQ MRD volumes up 43% year over year to 36.1k, ASPs of $1,382 per test, and sequencing gross margins of 71%, while 2026 MRD revenue guidance was raised to $268M-$278M. Beyond near-term growth, the planned split of the profitable MRD business from the non-core Immune Medicine segment, a $245M pharma backlog, expanding blood-based adoption, and improving reimbursement support a long runway for value creation.

Adaptive Biotechnologies is viewed negatively because the stock already trades at a significant premium multiple relative to historical Dx multiples, leaving little room for disappointment and amplifying downside risk if MRD growth fails to keep setting new records. The core clonoSEQ franchise remains dependent on continued investor enthusiasm, yet slower-than-expected customer adoption, reimbursement or guideline hurdles, and new competition could pressure the main revenue engine just as specialty lab stocks remain volatile. Separately, the planned separation of the Immune Medicine business by YE'26 adds execution uncertainty, and broader sector risks such as delayed R&D budgets, weaker hospital purchasing, and regulatory friction could further impair sentiment and profitability.